Proteomics Study of Mild Cognitive Impairment and Alzheimer's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age55+
SponsorGuangzhou University of Traditional Chinese Medicine
About this trial
This study intends to adopt standardized and rigorous cross-sectional research, collect biological specimens (including blood, feces, urine, saliva and tongue coating) from eligible subjects, and use liquid chromatography/mass spectrometry (LC-MS/MS) technology to explore early warning indicators of protein in patients with mild cognitive impairment and Alzheimer's disease
Eligibility criteria
Qualifiers
Older than 55-year-old，male or female.
patients meet the diagnosis of mild cognitive impairment (MCI) or Alzheimer's disease(AD) or whose family members were diagnoed with AD
Complete self-rating scale for memory impairment (AD-8 scale)
Those who agree to participate in clinical research and sign informed consent.
Disqualifiers
Patients with acute cardiovascular and cerebrovascular diseases, acute infections (pneumonia, urinary tract infection, oral infection, digestive tract infection), severe renal dysfunction, and uremia;
Pregnant or lactating women;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
650 Participants
are grouped into 4 trial groupsSponsors and collaborators
Guangzhou University of Traditional Chinese Medicine
Lead sponsor
Guangzhou Cadre Health Management Center
Collaborator
Source ClinicalTrials.gov